AbbVie, Inc. (ABBV) and Neomorph, Inc. have announced a strategic collaboration and an option-to-license agreement designed to develop innovative molecular glue degraders for a range of targets in the fields of oncology and immunology.
This partnership capitalizes on AbbVie's extensive knowledge in oncology and immunology drug development, while integrating Neomorph's state-of-the-art molecular glue discovery platform.
According to the agreement's terms, Neomorph will receive an upfront payment from AbbVie. Furthermore, Neomorph stands to gain up to $1.64 billion through aggregate option fees and milestone payments, alongside tiered royalties based on net sales.
Molecular glue degraders represent a pioneering class of small molecules engineered to precisely target and induce the degradation of proteins that fuel cancer progression or disrupt immune system balance, thereby offering a more targeted therapeutic approach.
These degraders hold the potential to address proteins that have previously been considered "undruggable."
